COMPASS Pathways plc filings document the regulatory record for a biotechnology company developing COMP360, a proprietary synthetic psilocybin formulation for mental health indications including treatment-resistant depression. Current reports disclose financial results, clinical and regulatory updates, investor presentation materials, and material agreements tied to debt facilities and securities offerings.
Proxy and other filings cover annual general meeting matters, board structure, committee assignments, compensation arrangements, and shareholder voting procedures. Capital-structure disclosures include American Depositary Shares, ordinary shares, pre-funded warrants, registration statement references, underwriting terms, and loan and security agreement amendments.
COMPASS Pathways plc reporting persons RTW Investments, LP and Roderick Wong, M.D. report beneficial ownership of 12,971,571 shares, representing 9.9% of the class, assuming exercise of 2,339,181 warrants. The percentage is calculated using 128,923,295 shares outstanding as of March 17, 2026.
The filing states the reported shares are held by the RTW Funds and that the RTW Funds have the right to receive dividends or sale proceeds. Shared voting and dispositive power for the reported shares is listed as 12,971,571 for both Reporting Persons.
Compass Pathways reported a strong start to 2026, combining major regulatory progress for its COMP360 psilocybin treatment in treatment-resistant depression with a sharp improvement in reported results. The FDA granted a rolling New Drug Application submission and review, which is already underway, and a Commissioner’s National Priority Voucher that may shorten review timelines.
Part B 26-week data from the COMP006 Phase 3 trial are expected in early Q3 2026, with final NDA submission still targeted for Q4 and launch readiness by year-end. Cash and cash equivalents rose to $466.0 million as of March 31, 2026, supporting a runway into 2028. For the quarter, research and development expenses were $26.5 million and general and administrative expenses were $16.4 million, while a non-cash $130.9 million warrant fair value gain drove net income of $91.2 million versus a prior-year net loss.
Compass Pathways plc reports strong Q1 2026 results, with net income of $91.2 million, driven primarily by a $130.9 million non-cash gain from the fair value change of warrant liabilities. Core operations still produced a loss from operations of $42.9 million as the company continues investing in late-stage development.
Cash and cash equivalents rose to $466.0 million, supported by warrant exercises, a February 2026 underwritten ADS offering, and a new Hercules loan tranche, lifting total assets to $531.7 million. Management believes this cash should fund operating expenses and capital needs into 2028.
Clinically, Compass advanced its COMP360 psilocybin program in treatment-resistant depression, with both pivotal Phase 3 trials (COMP005 and COMP006) meeting primary endpoints and the FDA granting rolling review and a Commissioner’s National Priority Voucher. The company is also initiating a Phase 2b/3 COMP360 trial in PTSD while maintaining a substantial accumulated deficit of $731.4 million.
COMPASS Pathways plc has issued its 2026 proxy statement for the Annual General Meeting on May 27, 2026 in London. Shareholders are asked to re-elect directors Justin Gover, Daphne Karydas and Jeffrey Jonas and elect new director Kathleen Tregoning to staggered multi‑year terms.
Other proposals seek re-appointment of PricewaterhouseCoopers LLP as U.K. statutory auditor, ratification of PwC US as independent registered public accounting firm, authorization for the Audit and Risk Committee to set auditor pay, and receipt of U.K. statutory annual accounts. Shareholders will also cast advisory votes on the U.K. directors’ remuneration report and on executive compensation. The Board recommends voting in favor of all 10 proposals and notes that no dividend is recommended for the year ended December 31, 2025.
COMPASS Pathways plc reported that Chief Executive Officer Kabir Nath received new equity-based compensation. He was granted options to purchase 367,815 Ordinary Shares at an exercise price of $5.64 per share, vesting in forty-eight equal monthly installments beginning on April 26, 2026.
He was also granted 175,000 Ordinary Shares in the form of Restricted Share Units under the 2020 Share Option and Incentive Plan. These RSUs vest in four equal annual installments, with the first installment vesting on March 26, 2027. Following the RSU grant, he directly holds 366,990 Ordinary Shares.
Compass Pathways plc reported that Chief Medical Officer Guy Goodwin received two new stock option awards. He was granted options over 55,000 ordinary shares at an exercise price of 0.01 per share and options over 115,600 ordinary shares at an exercise price of 5.64 per share.
The 55,000-share nominal cost option vests in four equal annual installments beginning on March 26, 2027. The 115,600-share option vests in 48 equal monthly installments beginning on April 26, 2026. Each ordinary share may be represented by one American Depositary Share. No open-market purchases or sales were reported in this filing.
Compass Pathways plc Chief Financial Officer Teri Loxam received new equity awards as part of compensation. She was granted share options covering 157,635 Ordinary Shares at an exercise price of $5.64 per share, expiring on March 25, 2036. These options vest in forty-eight equal monthly installments beginning on April 26, 2026.
She also received 75,000 Restricted Share Units (RSUs), each representing one Ordinary Share, with vesting in four equal annual installments starting on March 26, 2027. Following this RSU grant, she directly owns 152,002 Ordinary Shares. The company notes that Ordinary Shares may be represented by American Depositary Shares, each currently representing one Ordinary Share.
Compass Pathways is a clinical-stage biotech focused on its investigational COMP360 psilocybin treatment for serious mental health conditions, primarily treatment‑resistant depression (TRD) and PTSD. The company completed enrollment in two Phase 3 TRD trials and reported that both achieved their primary endpoints on the MADRS depression scale.
In COMP005, a single 25 mg dose of COMP360 showed a highly statistically significant and clinically meaningful MADRS improvement versus placebo at week 6, with durable effects through 26 weeks after one or two doses. In COMP006, two 25 mg doses given three weeks apart outperformed 1 mg on MADRS at week 6, also with rapid onset. COMP360 has generally shown a tolerable safety profile, with most adverse events mild or moderate and resolving within a day.
Based on these data, Compass plans to complete a rolling NDA submission for TRD in the fourth quarter of 2026 and is accelerating U.S. launch planning. The FDA has also accepted an IND for a Phase 2b/3 PTSD trial after an open‑label Phase 2 study showed large, durable reductions in CAPS‑5 PTSD severity and functional impairment.
Compass Pathways reported a much larger full-year 2025 net loss of $287.9 million (vs. $155.1 million in 2024), driven mainly by a $122.6 million non-cash fair value loss on warrant liabilities. Operating expenses were broadly flat, with R&D at $118.4 million and G&A at $60.6 million.
Cash and cash equivalents were $149.6 million at December 31, 2025, with debt of $31.6 million at that date (and $50.4 million by March 24, 2026). After a $150 million financing and $200 million warrant exercises, the company expects its cash position as of March 24, 2026 to fund operations into 2028.
Clinically, COMP360 achieved positive Phase 3 results in treatment‑resistant depression across large trials, showing rapid and durable responses with a generally well-tolerated safety profile. Compass plans a rolling NDA submission with completion expected in Q4 2026, aims to be launch-ready by the end of 2026, and is initiating a Phase 2b/3 PTSD trial following FDA IND acceptance.